Diagenode

Non-coding recurrent mutations in chronic lymphocytic leukaemia.


Xose S. Puente, Silvia Beà, Rafael Valdés-Mas, Neus Villamor, Jesús Gutiérrez-Abril et al.

Chronic lymphocytic leukaemia (CLL) is a frequent disease in which the genetic alterations determining the clinicobiological behaviour are not fully understood. Here we describe a comprehensive evaluation of the genomic landscape of 452 CLL cases and 54 patients with monoclonal B-lymphocytosis, a precursor disorder. We extend the number of CLL driver alterations, including changes in ZNF292, ZMYM3, ARID1A and PTPN11. We also identify novel recurrent mutations in non-coding regions, including the 3' region of NOTCH1, which cause aberrant splicing events, increase NOTCH1 activity and result in a more aggressive disease. In addition, mutations in an enhancer located on chromosome 9p13 result in reduced expression of the B-cell-specific transcription factor PAX5. The accumulative number of driver alterations (0 to ≥4) discriminated between patients with differences in clinical behaviour. This study provides an integrated portrait of the CLL genomic landscape, identifies new recurrent driver mutations of the disease, and suggests clinical interventions that may improve the management of this neoplasia.

Tags
Antibody

Share this article

Published
July, 2015

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410003-50
    H3K4me3 polyclonal antibody - ChIP-seq Grade
  • Antibody ChIP-seq grade icon
    C15410194
    H3K4me1 polyclonal antibody - ChIP-seq Grade
  • Antibody ChIP-seq grade icon
    C15410196
    H3K27ac polyclonal antibody - ChIP-seq Grade

Events

  • EpiChrom
    Umea Sweden
    Feb 27-Feb 28, 2020
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics